Diagnostiskt Centrum Hud

Diagnostiskt Centrum Hud (DCH), based in Sweden, specializes in dermatological care, providing expert diagnosis and treatment for various skin conditions through a network of clinics across the country. Founded in 2012 and headquartered in Stockholm, Sweden, Diagnostiskt Centrum Hud focuses on delivering specialized dermatological services. The company has participated in 2 notable deals, with the most recent being a minority investment from Bridgepoint in November 2020. The current CEO is Serdil Öcmaz, and the founder, Magnus Bäcklund, has previously established other ventures in the healthcare sector.

Diagnostiskt Centrum Hud offers a comprehensive range of dermatological services aimed at diagnosing and treating skin conditions such as acne, psoriasis, and skin cancer. Services are delivered by specialists in dermatology, ensuring high-quality care through various clinics located in major Swedish cities including Stockholm, Gothenburg, Malmö, and Helsingborg. In the fiscal year 2024, Diagnostiskt Centrum Hud reported a revenue of USD 14. 82 mn and an EBITDA of USD 1.

19 mn, reflecting its direct-to-consumer engagement model for dermatological services. Patients can access services through private consultations and referrals from general practitioners, with a focus on personalized care and patient retention. With the recent investment from Bridgepoint in November 2020, Diagnostiskt Centrum Hud plans to expand its operations across northern Europe. The funds will be utilized to support the development of new services and enhance the existing clinic network, aiming to reach new markets and further improve patient access to dermatological care.